PMGC (NASDAQ:ELAB) Stock Falls 1.6% – Time to Sell?

PMGC Holdings Inc. (NASDAQ:ELAB) shares fell 1.6% on Friday. The company traded as low as $3.07 and last traded at $3.08. Approximately 4,051 shares traded hands during trading, a decline of 93% from the average daily volume of 56,892 shares. The stock had previously closed at $3.13.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PMGC in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

PMGC Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.36 and a quick ratio of 1.30. The stock has a market cap of $2.49 million, a price-to-earnings ratio of -0.00 and a beta of -0.27. The firm has a fifty day moving average of $5.75 and a 200 day moving average of $16.49.

Institutional Trading of PMGC

A hedge fund recently bought a new stake in PMGC stock. Citadel Advisors LLC purchased a new position in shares of PMGC Holdings Inc. (NASDAQ:ELAB) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 20,702 shares of the company’s stock, valued at approximately $25,000. Citadel Advisors LLC owned 2.56% of PMGC as of its most recent SEC filing. Institutional investors and hedge funds own 22.22% of the company’s stock.

About PMGC

Elevai Labs, Inc, formerly known as PMGC Holdings, Inc, is a biotechnology and medical aesthetics company focused on developing and commercializing innovative skincare products and aesthetic treatments. The company combines biotechnology, regenerative medicine and cosmetic science to address skin health, rejuvenation and related aesthetic needs.

Elevai Labs’ product development activities include topical skincare formulations and professional-use products designed for aesthetic providers.